STIMULATION OF SECRETORY IGA AND SECRETORY COMPONENT OF IMMUNOGLOBULINS IN SMALL-INTESTINE OF RATS TREATED WITH SACCHAROMYCES-BOULARDII
STIMULATION OF SECRETORY IGA AND SECRETORY COMPONENT OF IMMUNOGLOBULINS IN SMALL-INTESTINE OF RATS TREATED WITH SACCHAROMYCES-BOULARDII
复制标题
DOI：
10.1007/bf01536771
复制
发表时间：
1990-02-01
影响因子：
3.1
通讯作者：
DIVE, C
中科院分区：
文献类型：
--
作者：
BUTS, JP;BERNASCONI, P;DIVE, C
布拉酵母（Saccharomyces boulardii，S.b.）在西欧国家主要用于治疗急性感染性肠炎和腹泻引起的胃肠道疾病。探讨S.b.针对肠道病原体感染，我们评估了分泌型伊加（s-IgA）的肠道分泌和免疫球蛋白（SC）的分泌组分对口服高剂量（0.5mg/g体重，每天三次）S. B.生长中的老鼠S.B.细胞（生物活性：2.8 ×109个活细胞/100 mg），从产后第14天至第22天每天通过胃插管给予断乳大鼠。对照组按照相同的时间表接受0.9%盐水或卵清蛋白。以每毫克细胞蛋白表示，从空肠分离的隐窝细胞中的SC含量显著增加（48.5% vs盐水对照，P < 0.05），因为在用S. b.处理的大鼠的十二指肠液中SC含量显著增加（62.8% vs盐水对照，P < 0.01）。口服S.b.治疗对肝脏分泌SC无影响。在S. b.细胞中s-IgA的平均浓度比生理盐水对照中测量的s-IgA浓度增加56.9%（P < 0.01）。与产后第14天至第22天用与Sb细胞提供的总蛋白质负荷相当的卵清蛋白抗原负荷（0.05 mg蛋白质/g体重，每天三次）处理的对照大鼠相比，S.b.-小肠绒毛细胞中SC含量为69%（P < 0.025），隐窝细胞中SC含量为80%（P < 0.01）。肠SC s-IgA浓度的这些变化似乎不是由于肠上皮细胞周转率的增加，因为在空肠、回肠和结肠中测量的粘膜质量参数和[3 H]胸苷掺入DNA的速率在S.b.-治疗的老鼠我们的研究结果表明，S.B.在胃肠道中发挥其免疫保护作用是刺激肠道分泌s-IgA和免疫球蛋白的分泌组分。
Saccharomyces boulardii (S.b.) is largely used in Western European countries for the treatment of acute infectious enteritis and antibiotic-induced gastrointestinal disorders. To study the mechanisms of the protective effect of S.b. against enteral pathogen infection, we assessed the response of the intestinal secretion of secretory IgA (s-IgA) and of the secretory component of immunoglobulins (SC) to oral administration of high doses (0.5 mg/g body weight, three times per day) of S.B. cells in growing rats. S.b. cells (biological activity: 2.8 .times. 109 viable cells/100 mg) were administered daily by gastric intubation ot weanling rats from day 14 until day 22 postpartum. Control groups received either 0.9% saline or ovalbumin following the same schedule. Expressed per milligram of cell protein, SC content was significantly increased in crypt cells isolated from the jejunum (48.5% vs saline controls, P < 0.05) as it was in the duodenal fluid (62.8% vs saline controls P < 0.01) of rats treated with S.b. Oral treatment with S.b. had no effect on the secretion of SC by the liver. In the duodenal fluid of rats treated with S.b. cells, the mean concentration of s-IgA was increased by 56.9% (P < 0.01) over the concentration of s-IgA measured in saline controls. Compared to control rats treated from day 14 until day 22 postpartum with an antigenic load of ovalbumin equivalent to the total protein load provided by Sb cells (0.05 mg protein/g body weight, three times per day), S.b.-treated rats also exhibited a significantly higher intestinal concentration of SC (69% in villus cells, P < 0.025 and 80% in crypt cells, P < 0.01). These changes in intestinal SC s-IgA concentration appeared not to be due to an increase in enterocyte turnover rate, since the mucosal mass parameters and the incorporation rate of [3H]thymidine into DNA measured in the jejunum, ileum, and colon remained unchanged in S.b.-treated rats. Our findings suggest that one of the mechanisms by which S.B. exerts its immunoprotective effect in the gastrointestinal tract is a stimulation of intestinal secretion of s-IgA and of the secretory component of immunoglobulins.